Fig 1: Reconstitution of ILC2 or EOS reduces AAA growth in ILC2-deficient Rorafl/flIl7rCre/+ mice. A) Aortic diameter and length, and representative images of Rorafl/flIl7rCre/+ mice treated with or without WT EOS or ILC2 from WT and Il5-/- mice. Power: 1.000. B) ILC2 sorting strategy from WT splenocytes. ILC2 were defined as CD45+Lin- ICOS+CD127+KLRG1+ cells and isolated from CD45.1 transgenic mice. Donor CD45.1+ ILC2 cells were used to monitor their accumulation in Rorafl/flIl7rCre/+ mouse AAA lesions by CD45.1 immunofluorescent staining. C) FACS demonstrated the purity of bone-marrow-derived CD11b+Siglec-F+ EOS after 12 d differentiation. Donor CD45.1+ EOS were also detected in Rorafl/flIl7rCre/+ mouse AAA lesions using CD45.1 immunofluorescent staining. D) FACS analysis of blood donor CD45.1+ ILC2 or EOS in Rorafl/flIl7rCre/+ mice at 7 d after reconstitution and peri-aortic CaPO4 injury. E/F) FACS analysis of donor CD45.1+ EOS in blood and CD45.1+ ILC2 in aorta from Rorafl/flIl7rCre/+ recipient mice at different days (1, 3, 5, 7) after donor cell adoptive transfer. FACS analysis of G) CD11b+Siglec-F+ EOS, H) CD11b+Ly6Chi and CD11b+Ly6Clo monocytes, I) CD11c+MHC-II+ DCs, and J) CD11b+Ly6G+ neutrophils in AAA lesions from Rorafl/flIl7rCre/+ mice with or without receiving donor EOS or ILC2 from WT and Il5-/- mice. Data are mean±SEM, n = 10–25 per group, *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA test for normal distributed samples (after Shapiro–Wilk test) followed by A,F–I) LSD correction or E) nonparametric Mann–Whitney U test.